Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-CVOT: Tirzepatide vs Dulaglutide on MACE in Type 2 Diabetes
NCT04255433Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2020
- Primary completion
- Jun 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 31
01
Overview
Phase 3, randomised trial of tirzepatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Major Adverse Cardiovascular Events at 259 weeks. Started May 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04255433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04255433.